Diamyd Logo
This website is only intended for investors

Fighting diabetes

Diamyd Medical is a diabetes company active in the field of pharmaceutical development. The Company is headquartered in Stockholm, Sweden and shares are listed on NASDAQ OMX First North (ticker: DMYD B).
Enrolment is expected to be completed by summer, and initial results from the DIABGAD-1 study are expected in 2015
Diabetes is associated with serious complications due to elevated and fluctuating blood sugar levels, causing substantial suffering and extensive costs for society.
Diamyd Medical was able to start the New Year by announcing that more than half of the planned total of 60 patients in the DIABGAD-1 study had been enrolled. Children and adolescents with newly diagnosed...
Diamyd® is a GAD-based therapy under development for the treatment and prevention of autoimmune diabetes such as type 1 diabetes and LADA. Treatment with Diamyd® aims to intervene in the autoimmune...
rss icon
    
pdf icon
22 januari 2014, 08:30
Delårsrapport I 13/14